Abstract: An apparatus and method for producing hydrocarbons including aromatic hydrocarbons and lower olefins including propylene from CH4 and CO2 through CO and H2 with high activity and high selectivity.

Abstract: A catalyst structure that allows prevention of aggregation of fine particles of a functional substance, suppresses decrease of catalyst activity, and thus enables extension of the lifetime of the catalyst structure. A catalyst structure has a carrier that is formed from a zeolite-type compound and has a porous structure. The functional substance includes a first element that is at least one metallic element selected from the group consisting of cobalt (Co), nickel (Ni), iron (Fe), and ruthenium (Ru), and at least one second element selected from the group consisting of metallic elements in group 1, group 2, group 4, group 7, and group 12 on the periodic table. The carrier has paths connected to each other. The functional substance is present in at least the paths of the carrier.

Abstract: Provided is a vaccine for preventing and/or treating infection with human T-cell leukemia virus type 1 (HTLV-1). A lipid particle encapsulating a nucleic acid expressing a gp46 antigen or a Tax antigen of human T-cell leukemia virus type 1 (HTLV-1), wherein the lipid comprises a cationic lipid represented by general formula (Ia): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group optionally having one or more C2-C4 alkanoyloxy groups, or a C10-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; and p is 3 or 4.

Abstract: A polyimide resin composition having a polyimide resin (A) and a polyether sulfone resin (B), wherein the polyimide resin (A) comprises a repeating structural unit of formula (1) and a repeating structural unit of formula (2), a content ratio of the repeating structural unit of the formula (1) with respect to the total of the repeating structural unit of the formula (1) and the repeating structural unit of the formula (2) is 20 to 70 mol %, and a mass ratio of the component (A) to the component (B), [(A)/(B)], is 0.1/99.9 to 65/35; and a molded article containing the same: where R1 represents a divalent group of 6 to 22 carbon atoms with an alicyclic hydrocarbon structure; R2 represents a divalent chain aliphatic group of 5 to 16 carbon atoms; and X1 and X2 each independently represent a tetravalent group of 6 to 22 carbon atoms and having an aromatic ring.

Abstract: As a technique enabling to simply and accurately diagnose human T cell leukemia virus type 1 (HTLV-1) related disease, there is provided a diagnostic method for an HTLV-1 related disease based on an amount of tumor necrosis factor receptor 2 (TNFR2) in a blood sample taken from a subject, wherein (1) it is determined based on an increase of the amount of TNFR2 that the subject suffers from, or is likely to develop, the HTLV-1 related disease; and/or (2) it is determined based on a decrease of the amount of TNFR2 that the subject is in remission, or is likely to be in remission, of the HTLV-1 related disease.

Abstract: As a technique enabling to simply and accurately diagnose human T cell leukemia virus type 1 (HTLV-1) related disease, there is provided a diagnostic method for an HTLV-1 related disease, comprising the steps of: measuring the amount of a marker protein in a blood sample taken from a subject, wherein the marker protein is at least one selected from the proteins listed in Tables 1 and 2; and, if a measured value is a predetermined reference value or more or the predetermined reference value or less, determining that the subject suffers from the HTLV-1 related disease or determining that the subject is in remission of the HTLV-1 related disease.